SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease
Sophia Weiner(Institute of Neurobiology), Johan Gobom(Sahlgrenska University Hospital), Julius Constantinescu(University of Gothenburg), Gunnar Brinkmalm(University of Gothenburg), Bárbara Fernandes Gomes(University of Gothenburg), Kaj Blennow(Sahlgrenska University Hospital), Mathias Sauer(Sahlgrenska University Hospital), Bengt Nellgård(Sahlgrenska University Hospital), Keti Dalla(Sahlgrenska University Hospital), Douglas Galasko(University of Minnesota), Bruno Becker(Sahlgrenska University Hospital), Henrik Zetterberg(University of Wisconsin–Madison), Radu Constantinescu(Sahlgrenska University Hospital)
Cited by 9
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k